Form 4: Adagio Medical Holdings Director, Orly Mishan, Acquires 300,000 Stock Options

Director Orly Mishan of Adagio Medical Holdings acquires 300,000 non-qualified stock options under the company's 2024 Equity Incentive Plan.

Summary

• Orly Mishan, a director of Adagio Medical Holdings, acquired 300,000 non-qualified stock options on March 20, 2025.
• The options were granted under the company's 2024 Equity Incentive Plan and approved by the Compensation Committee on the same date.
• The exercise price of the options is $0.865.
• The options vest monthly over a three-year period, starting July 31, 2024, with 1/36th of the shares vesting each month of continuous service.
• The options expire on July 31, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting a stable and incentivized leadership structure. This is generally viewed positively.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the medical device industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Companies like Medtronic and Boston Scientific also utilize stock options as part of their compensation strategy to align executive interests with shareholder value.
• The vesting schedule of three years is fairly standard in the industry.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• Employees may view the grant positively as it signals investment in leadership.

Key Dates

Keywords

stock options, Adagio Medical Holdings, director, Orly Mishan, equity incentive plan, Form 4, ADGM